Allergan selects GCI Health to support launch of BOTOX® for Chronic Migraine

18 October, 2010


NEW YORK, NY — GCI Health, a healthcare public relations agency, has been selected by Allergan, Inc., to support the FDA approval and launch of BOTOX® (onabotulinumtoxinA) for the prophylactic (preventive) treatment of headaches in adults with Chronic Migraine. The FDA approved BOTOX® for this indication on October 15, 2010. The account will be serviced out of GCI Health’s New York and West Coast offices.

BOTOX® is the first clinically studied prophylactic treatment to be approved by the FDA specifically for patients who have a history of migraine and suffer from headaches on 15 or more days per month with headaches lasting four hours a day or longer. This FDA approval marks the sixth therapeutic indication for the product in the United States since 1989.

“Chronic Migraine is a debilitating neurological condition that, despite affecting millions of Americans, is grossly under-diagnosed, which can delay proper treatment,” said Wendy Lund, chief executive officer at GCI Health. “Allergan is in an unprecedented position with BOTOX® to address this challenge, and our team is passionate about the opportunity to shine a light on the misery of the patient experience and better define the disease.”


About GCI Health
GCI Health is a forward-thinking healthcare public relations agency powered by ‘best-in-the-business’ professionals and the only WPP company that specializes in healthcare public relations. With over 65 professionals in offices in New York, Los Angeles, San Francisco, San Diego, Atlanta and the U.K., GCI Health offers clients an accessible senior level leadership team, A to Z healthcare experience, a commitment to “beating” client expectations, and an obsession with anticipating the challenges of an increasingly complex and transforming healthcare communications environment. With insider’s knowledge of high science, digital health strategy, crisis management, patient advocacy, health education and consumer activation, GCI Health’s focus on delivering results is unrelenting and second to none. For more information, please visit www.gcihealth.com.  

Contact
Janine Katz, GCI Health
+1 (732) 861-3806
Janine.katz@gcihealth.com

Acrobat Document gci_pressrelease_allergran_oct10_guid70586c1afc834.pdf


Tools Print page E-mail page Press Releases Reading Room Get Acrobat Reader

WPP Pro Bono Work 2015

WPP Pro Bono
WPP Sustainability Report 2015/2016

WPP Sustainability Report 2015-2016
WPP Annual Report & Accounts 2015

WPP Annual Report 2015